ClinicalTrials.gg
CompletedNCT03749252Updated Jun 1, 2022Results posted

Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI

A Phase 2 interventional study of P03277 in Central Nervous System Indication, Pediatric Patients and Body Indication, sponsored by Guerbet. Completed at 16 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Guerbet · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Study summary

This is a pharmacokinetics (PK), open-label, uncontrolled, multicenter phase II trial with age-staggered approach.

The primary objective is to evaluate the PK profile of gadopiclenol in plasma following single IV injection of 0.05 mmol/kg body weight (BW) in pediatric population aged from 2 to 17 years undergoing CNS contrast-enhanced MRI (CNS cohort).

Read the detailed description

A population PK approach and an age-down staggered approach will be used. Patients will be recruited into 3 predefined age groups: 12-17, 7-11 and 2-6 years. The inclusions will start with the older group (Adolescents, 12-17 years), followed by Preadolescents (7-11 years) and finally Young Children (2-6 years of age).

02

Conditions studied

  • Central Nervous System Indication
  • Pediatric Patients
  • Body Indication
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

To be included in the study, the patient had to meet all the following criteria:

  1. Female or male pediatric patient aged 2 to 17 years,
  2. Patient with known or suspected lesion(s) scheduled to undergo routine contrast-enhanced MRI of CNS or of other organs including at least one organ among head and neck, thorax, abdomen, pelvis or musculoskeletal system (including extremities),
  3. Patient whose parent(s) or legal guardian having read the information, provided their consent to patient's participation in writing by dating and signing the prior to any trial related procedure being conducted,
  4. Patient with capacity of understanding who received age- and maturity-appropriate information and provided his/her assent to participate in the trial (as required by national regulations),
  5. Patient affiliated to national health insurance according to local regulatory requirements.

Non-inclusion Criteria:

Patients could not be included in the study if they presented with one or more of the following non-inclusion criteria:

  1. Patient planned for treatment or procedure (e.g., surgery) that would prevent obtaining the required blood samples or performing other trial procedures between the screening visit and up to 1 day after gadopiclenol administration,
  2. Patient undergoing treatment or procedure (e.g., diuretics, blood loss or blood transfusion) preceding or subsequent to gadopiclenol administration that would alter gadopiclenol PK parameters,
  3. Patient with acute or chronic renal insufficiency defined as estimated (eGFR) out of age-adjusted normal ranges (eGFR calculated with bedside Schwartz equation),
  4. Patients referred for MR Angiography,
  5. Patient with history of bleeding disorder,
  6. Patient with known severe liver disease,
  7. Patient with known cardiac disease (e.g., heart rhythm anomalies, long syndrome),
  8. Patient with any clinically significant abnormal 12-lead that in the Investigator's opinion would affect the safety evaluation or place the patient at risk,
  9. Patient with electrolyte or fluid imbalance that at Investigator's judgment presents undue risk assessed within 1 month prior to gadopiclenol administration,
  10. Patient undergoing a change in chemotherapy within 1 day prior to or 1 day after gadopiclenol administration,
  11. Patient who received any other contrast agent for CT and/or MRI within 1 week prior to or 1 week after gadopiclenol administration,
  12. Patient with for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker),
  13. Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs,
  14. Patient with history of caused by any contrast media / agents (iodinated or gadolinium-based),
  15. Patient with known contraindication(s) to the use of any GBCA,
  16. Pregnant or breast-feeding female patient (female patient with [who experienced menarche] must have a negative urine pregnancy test within 24 hours prior to gadopiclenol administration and must be using medically approved * if sexually active),
  17. Patient with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the patient's safety or her/his ability to participate to the whole trial,
  18. Patient unlikely to comply with the protocol, e.g., uncooperative attitude of parent(s) or legal guardian, inability to return for follow-up visits and unlikelihood of completing the trial,
  19. Having participated in a clinical trial and having received any product within 7 days prior to gadopiclenol administration or planned during the trial,
  20. Patient previously included in this trial,
  21. Patient related to the Investigator or any other trial staff or relative directly involved in the trial conduct.

    • medically approved contraception methods include: female sterilization, use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception, placement of an Intrauterine Device (IUD) or Intrauterine System (IUS), barrier methods of contraception (condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    CNS Cohort 2-6 years

    Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI

    Drug: P03277

  • Experimental
    CNS Cohort 7-11 years

    Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI

    Drug: P03277

  • Experimental
    CNS Cohort 12-17 years

    Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI

    Drug: P03277

  • Experimental
    Body Cohort 2-6 years

    Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)

    Drug: P03277

  • Experimental
    Body Cohort 7-11 years

    Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)

    Drug: P03277

  • Experimental
    Body Cohort 12-17 years

    Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)

    Drug: P03277

Interventions

  • DrugP03277

    A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

    Also known as: gadopiclenol

06

What researchers measure

Primary outcomes

  1. Elimination Half-life

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours

  2. Total Clearance

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours

  3. Central Volume of Distribution

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours

  4. Peripheral Volume of Distribution

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours

  5. Area Under the Curve

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours

  6. Simulated Concentrations 10 Minutes Post-injection

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 10 minutes post-injection

  7. Simulated Concentrations 20 Minutes Post-injection

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 20 minutes post-injection

  8. Simulated Concentrations 30 Minutes Post-injection

    P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

    Time frame: 30 minutes post-injection

07

Results

Posted Jun 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneCNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 Years
Started262331
Completed262331
Not completed000

Outcome measures

PrimaryElimination Half-life

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Reported as:
Median · hours
Elimination Half-life
hoursCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Elimination Half-life1.29 (0.69 to 3.38)1.48 (0.83 to 3.20)1.77 (1.00 to 3.57)
PrimaryTotal Clearance

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Reported as:
Median · L/h/kg
Total Clearance
L/h/kgCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Total Clearance0.12 (0.05 to 0.28)0.10 (0.04 to 0.24)0.08 (0.04 to 0.20)
PrimaryCentral Volume of Distribution

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Reported as:
Median · L/kg
Central Volume of Distribution
L/kgCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Central Volume of Distribution0.12 (0.06 to 0.26)0.12 (0.06 to 0.24)0.11 (0.05 to 0.24)
PrimaryPeripheral Volume of Distribution

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Reported as:
Median · L/kg
Peripheral Volume of Distribution
L/kgCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Peripheral Volume of Distribution0.06 (0.06 to 0.06)0.06 (0.06 to 0.06)0.06 (0.06 to 0.06)
PrimaryArea Under the Curve

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Reported as:
Mean · mg.h/L
Area Under the Curve
mg.h/LCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Area Under the Curve403.16 ± 93.35477.25 ± 105.71582.30 ± 122.08
PrimarySimulated Concentrations 10 Minutes Post-injection

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
10 minutes post-injection
Reported as:
Mean · mg/L
Simulated Concentrations 10 Minutes Post-injection
mg/LCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Simulated Concentrations 10 Minutes Post-injection302.11 ± 44.68327.20 ± 47.95349.15 ± 52.59
PrimarySimulated Concentrations 20 Minutes Post-injection

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
20 minutes post-injection
Reported as:
Mean · mg/L
Simulated Concentrations 20 Minutes Post-injection
mg/LCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Simulated Concentrations 20 Minutes Post-injection234.88 ± 30.18259.67 ± 32.02285.16 ± 35.35
PrimarySimulated Concentrations 30 Minutes Post-injection

P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.

Time frame:
30 minutes post-injection
Reported as:
Mean · mg/L
Simulated Concentrations 30 Minutes Post-injection
mg/LCNS Cohort 2-6 YearsCNS Cohort 7-11 YearsCNS Cohort 12-17 Years
Simulated Concentrations 30 Minutes Post-injection188.26 ± 25.10211.20 ± 25.82237.25 ± 26.97

Adverse events

Collected over Adverse events were recorded from informed consent signature untill the end of the study (up to 120 days after gadopiclenol administration).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CNS & Body Cohorts 2-6 Years0/26 (0%)1/26 (3.8%)4/26 (15.4%)
CNS & Body Cohorts 7-11 Years0/23 (0%)0/23 (0%)6/23 (26.1%)
CNS & Body Cohorts 12-17 Years0/31 (0%)2/31 (6.5%)4/31 (12.9%)
Most frequent serious events
Most frequent serious events
EventCNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 Years
Head injuryInjury, poisoning and procedural complications1/260/230/31
EpilepsyNervous system disorders1/260/230/31
ComaNervous system disorders1/260/230/31
Condition aggravatedGeneral disorders1/260/231/31
HydronephrosisRenal and urinary disorders0/260/231/31
TonsillitisInfections and infestations0/260/231/31
Most frequent other events
Showing 10 of 24
Most frequent other events
EventCNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 Years
PharyngitisInfections and infestations0/261/230/31
Tracheobronchitis mycoplasmalInfections and infestations0/261/230/31
Upper respiratory tract infectionInfections and infestations0/261/230/31
Condition aggravatedGeneral disorders0/261/230/31
Blood pressure increasedInvestigations0/261/230/31
Eosinophil count increasedInvestigations0/261/230/31
Neutrophil count decreasedInvestigations0/261/230/31
EpilepsyNervous system disorders0/261/230/31
CoughRespiratory, thoracic and mediastinal disorders0/261/230/31
PruritusSkin and subcutaneous tissue disorders0/261/230/31

Baseline characteristics

All patients who received gadopiclenol administration and underwent CNS or Body MRI

Age, Continuous
Age, Continuous(years)CNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 YearsTotal
Mean3.8 ± 1.38.8 ± 1.214.3 ± 1.69.3 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)CNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 YearsTotal
Female7131939
Male19101241
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 YearsTotal
Hispanic or Latino0000
Not Hispanic or Latino26233180
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CNS & Body Cohorts 2-6 YearsCNS & Body Cohorts 7-11 YearsCNS & Body Cohorts 12-17 YearsTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White26233180
More than one race0000
Unknown or Not Reported0000
08

Study locations

16 sites
  • MHAT Central Onco Hospital Ltd
    Plovdiv, Bulgaria
  • Acibadem City Clinic Tokuda Hospital
    Sofia, Bulgaria
  • MHAT Dr. Stoyan Kirkovich
    Stara Zagora, Bulgaria
  • Semmelweis Egyetem II. sz Gyermekgyogyaszati Klinika
    Budapest, Hungary
  • Markhot Ferenc Oktatokorhaz es Rendelointezet
    Eger, Hungary
  • B.-A.-Z. Megyei Korhaz Gyermek-Egeszsegugyi Kozpont
    Miskolc, Hungary
  • Szpital Uniwersytecki nr 1 w Bydgoszczy im. dr Jurasza, Oddział Kliniczny Chirurgii Ogólnej i Onkologicznej Dzieci i Młodzieży
    Bydgoszcz, Poland
  • Uniwersytecki Szpital Dziecięcy w Lublinie
    Lublin, Poland
  • Klinika Chirurgii Dziecięcej
    Rzeszów, Poland
  • Instytut "Pomnik -Centrum Zdrowia Dziecka"
    Warsaw, Poland
  • Zakład Radiologii PediatrycznejSamodzielny Publ. Dziecięcy Szp. Kliniczny w Warszawie
    Warsaw, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Łódź, Poland
  • II. Detská klinika SZU, Detská fakultná nemocnica s poliklinikou Banská Bystrica
    Banská Bystrica, Slovakia
  • Klinika detí a dorastu JLF UK a UNM, Univerzitná nemocnica Martin
    Martin, Slovakia
  • Faculty hospital Nitra, Clinic of neonates, children and adolescents
    Nitra, Slovakia
  • Children's City Clinical Hospital
    Dnipro, Ukraine
09

References and documents

Publications

  • Jurkiewicz E, Tsvetkova S, Grinberg A, Pasquiers B. Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years. Invest Radiol. 2022 Aug 1;57(8):510-516. doi: 10.1097/RLI.0000000000000865. Epub 2022 Mar 2. PubMed 35318970 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Dec 2019, 13 months.

Results were first posted in Jun 2022, 2 years 5 months after primary completion. A results delay was requested in Aug 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2018
First posted
Nov 21, 2018
StartActual
Nov 6, 2018
Primary completionActual
Dec 18, 2019
CompletionActual
Aug 10, 2020
Results delay requested
Aug 25, 2020
Results first posted
Jun 1, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03749252
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Nov 6, 2018
Primary completion
Dec 18, 2019
Completion
Aug 10, 2020
Results posted
Jun 1, 2022
Last update
Jun 1, 2022

Study contacts

Elżbieta Jurkiewicz, MD
principal investigator · Instytut Pomnik

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion